Zelira Therapeutics Statistics
Want to see AU:ZLD full AI Analyst Report?
Zelira Therapeutics (ZLD) Stock Statistics & Valuation Metrics
Total Valuation
Zelira Therapeutics has a market cap or net worth of AUD 5.95M. The enterprise value is AUD 7.48M.
- Market Cap
- AUD 5.95M
- Enterprise Value
- AUD 7.48M
Share Statistics
Zelira Therapeutics has 13,147,155 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,147,155
- Owned by Insiders
- 12.77%
- Owned by Institutions
- ―
Financial Efficiency
Zelira Therapeutics’s return on equity (ROE) is 0.81 and return on invested capital (ROIC) is 128.84%.
- Return on Equity (ROE)
- 0.81
- Return on Assets (ROA)
- -2.79
- Return on Invested Capital (ROIC)
- 128.84%
- Return on Capital Employed (ROCE)
- 0.92
- Revenue Per Employee
- 82
- Profits Per Employee
- -453.48K
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 1.68
Valuation Ratios
The current PE Ratio of Zelira Therapeutics is -1.56. Zelira Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -1.56
- PS Ratio
- 10020.70
- PB Ratio
- -1.29
- Price to FCF
- -1.34
- Price to Operating Cash Flow
- -1.17
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Zelira Therapeutics had revenue of 656 and earned -3.63M in profits. Earnings per share was -0.32.
- Revenue
- 656
- Gross Profit
- -802.95K
- Operating Income
- -3.95M
- Pretax Income
- -3.85M
- Net Income
- -3.63M
- EBITDA
- -4.05M
- Earnings Per Share (EPS)
- -0.32
Cash Flow
In the last 12 months, operating cash flow was -4.91M and capital expenditures -5, giving a free cash flow of -4.91M billion.
- Operating Cash Flow
- -4.91M
- Free Cash Flow
- -4.91M
- Free Cash Flow per Share
- -0.43
Dividends & Yields
Zelira Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -74.65%
- Earnings Yield
- -63.19%
Stock Price Statistics
- Beta
- 1.57
- 52-Week Price Change
- 51.52%
- 50-Day Moving Average
- 0.50
- 200-Day Moving Average
- 0.51
- Relative Strength Index (RSI)
- 38.53
- Average Volume (3m)
- ―
Important Dates
Zelira Therapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 02, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Zelira Therapeutics as a current ratio of 0.11, with Debt / Equity ratio of -48.01%
- Current Ratio
- 0.11
- Quick Ratio
- 0.02
- Debt to Market Cap
- 0.39
- Net Debt to EBITDA
- -0.53
- Interest Coverage Ratio
- -9.71
Taxes
In the past 12 months, Zelira Therapeutics has paid -1.15M in taxes.
- Income Tax
- -1.15M
- Effective Tax Rate
- 0.30
Enterprise Valuation
Zelira Therapeutics EV to EBITDA ratio is -2.15, with an EV/FCF ratio of -1.77.
- EV to Sales
- 13276.45
- EV to EBITDA
- -2.15
- EV to Free Cash Flow
- -1.77
- EV to Operating Cash Flow
- -1.77
Balance Sheet
Zelira Therapeutics has AUD 5,663.00 in cash and marketable securities with AUD 2.14M in debt, giving a net cash position of -AUD 2.14M billion.
- Cash & Marketable Securities
- AUD 5,663.00
- Total Debt
- AUD 2.14M
- Net Cash
- -AUD 2.14M
- Net Cash Per Share
- -AUD 0.16
- Tangible Book Value Per Share
- -AUD 0.41
Margins
Gross margin is -122400.15%, with operating margin of -602467.84%, and net profit margin of -553029.27%.
- Gross Margin
- -122400.15%
- Operating Margin
- -602467.84%
- Pretax Margin
- -586840.24%
- Net Profit Margin
- -553029.27%
- EBITDA Margin
- -617481.55%
- EBIT Margin
- -658713.11%
Scores
- Smart Score
- 6
- AI Score
- 39
